Alendronate (sodium hydrate)

[1]Fisher JE, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999 Jan 5;96 (1) :133-8|[2]Bergstrom JD, et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373 (1) :231-41.|[3]Keller RK, et al. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem Biophys Res Commun. 1999 Dec 20;266 (2) :560-3.|[4]Elliott SN, et al. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci. 1998;62 (1) :77-91.|[5]Stearns ME, et al. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis. 1996;16 (3) :116-31.

Am J Physiol Endocrinol Metab. 2024 May 8.|Bone. 2024 Nov 29:192:117348.|Int J Mol Sci. 2024 Jul 16;25 (14) :7798.|J Biol Chem. 2019 Jul 19;294 (29) :11240-11247.|J Med Chem. 2024 Sep 12;67 (17) :15738-15755.|Pathol Res Pract. 2025 Sep:273:156138.|Biochem Pharmacol. 2025 Aug 13;242 (Pt 1) :117234.|Int J Mol Med. 2025 Dec;56 (6) :206.|J Pharm Anal. 2025 Jul 31.|Cell Rep. 2022 Oct 25;41 (4) :111508.